A spate of royalty deals are changing the way certain biotechs press ahead. This trend seems to be an alternative to traditional biopharma fundraising.
Biotechs from all over the country as well as other parts of the world showcased recent pipeline advancements in oncology clinical trials at ASCO 2024.